Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Prospective Cohort Study of Neoadjuvant Therapy With Sintilimab (PD-1 Inhibitor) Combined With Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma

NCT06475196 is registered in ClinicalTrials.gov with Tang-Du Hospital as lead sponsor.

NCT NCT06475196
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06475196 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Prospective Cohort Study of Neoadjuvant Therapy With Sintilimab (PD-1 Inhibitor) Combined With Chemotherapy in Resectable Esophageal Squamous Cell Carcinoma
Lead sponsor
Tang-Du Hospital
Phase
Observational
Overall status
Unknown status
Start date
June 20, 2024
Completion date
June 20, 2025
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

resectable esophageal squamous cell carcinoma